

A Breakfast Symposium at the 2005 CCFA National Research and Clinical Conference:
4th Annual Advances in the Inflammatory Bowel Diseases


Aminosalicylates in Ulcerative Colitis:

New Options and Solutions to Old Problems

**Saturday,
December 3, 2005
Miami, Florida**

Fontainebleau Resort, Fontaine/Fleur de Lis
6:45 am - 8:00 am

Chair:
William J. Tremaine, MD
Mayo Clinic
Rochester, Minnesota



Aminosalicylates in Ulcerative Colitis:

New Options and Solutions to Old Problems

Saturday, December 3, 2005 Miami, Florida

Scientific Agenda

- 6:45 am** Welcome and introduction
William J. Tremaine, MD
- 6:50 am** How should the new
clinical endpoints effect
therapeutic decisions?
William J. Tremaine, MD
Mayo Clinic
Rochester, Minnesota
- 7:10 am** Impact of compliance data on
course of Ulcerative Colitis
Daniel H. Present, MD
Mount Sinai School of Medicine
New York, New York
- 7:30 am** Alone and in combination:
Emerging therapy options
with aminosalicylates
Arthur A. Kornbluth, MD
Mount Sinai School of Medicine
New York, New York
- 7:50 am** Panel discussion/questions
- 8:00 am** Adjourn

Symposium Organizer



Imedex[®]
education is the best medicine[®]

4325 Alexander Drive
30022 Alpharetta, Georgia, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com

Who Should Attend

This educational program is intended for gastroenterologist, internists, and other health care professionals in active clinical practice involving the management of patients with Inflammatory Bowel Disease (IBD).

Continuing Medical Education

Imedex[®], Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, Inc. designates this educational activity for a maximum of 1.25 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Objectives

After successful completion of this activity, participants should be able to:

- Update clinical decision making via appreciation of new clinical endpoints
- Discuss the impact of compliance data on the course of ulcerative colitis
- Implement novel therapeutic strategies with aminosalicylates

Corporate Support

Shire

This symposium is made possible by an unrestricted educational grant from Shire Pharmaceuticals. Shire Pharmaceuticals has been assigned meeting space to support an educational offering during the 4th Annual Advances in the Inflammatory Bowel Diseases Conference.

The assignment of meeting space does not imply product endorsement nor does Advances in the Inflammatory Bowel Diseases assume responsibility for the educational content.